Cone-Specific Promoters for Gene Therapy of Achromatopsia and Other Retinal Diseases

Human Gene Therapy

Volumn 27, Issue 1, 2016, Pages 72-82

  Ye, Guo Jie ^a   Budzynski, Ewa ^b   Sonnentag, Peter ^b   Nork, T Michael ^c,d   Sheibani, Nader ^c,d   Gurel, Zafer ^c   Boye, Sanford L ^e   Peterson, James J ^e   Boye, Shannon E ^e   Hauswirth, William W ^e   Chulay, Jeffrey D ^a  

^a APPLIED GENETIC TECHNOLOGIES CORPORATION   (United States)

^b 206 Carnegie Center   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d OSOD Ocular Services on Demand   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONE OPSIN; GREEN FLUORESCENT PROTEIN; PARVOVIRUS VECTOR; TRANSDUCIN; SCOTOPSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLOR BLINDNESS; CONTROLLED STUDY; ELECTRORETINOGRAPHY; GENE THERAPY; MOUSE; NONHUMAN; PHOTORECEPTOR; PRIMATE; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; RETINA CONE; RETINA DISEASE; SUBRETINAL DRUG ADMINISTRATION; ANIMAL; COLOR VISION DEFECTS; DEPENDOPARVOVIRUS; DOG; GENE EXPRESSION; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; METABOLISM; PATHOLOGY; RETINAL DISEASES;

ANIMALS; COLOR VISION DEFECTS; DEPENDOVIRUS; DOGS; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; PROMOTER REGIONS, GENETIC; RETINAL CONE PHOTORECEPTOR CELLS; RETINAL DISEASES; ROD OPSINS;

EID: 84955279982     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2015.130     Document Type: Article

References (32)

1. Kohl S, Jagle H, Sharpe LT, et al. Achromatopsia (www. ncbi. nlm. nih. gov/bookshelf/br. fcgi?book=gene& part=achm). In: Pagon RA, Bird TC, Dolan CR, Stephens K, editors. Gene Reviews [Internet]. (University of Washington, Seattle). 2013.
2. Kohl S, Varsanyi B, Antunes GA, et al. CNGB3 mutations account for 50%of all cases with autosomal recessive achromatopsia. Eur J Hum Genet 2005; 13:302-308.
3. Wissinger B, Gamer D, Jagle H, et al. CNGA3 mutations in hereditary cone photoreceptor disorders. Am J Hum Genet 2001;69:722-737.
4. Zelinger L, Greenberg A, Kohl S, et al. An ancient autosomal haplotype bearing a rare achromatopsiacausing founder mutation is shared among Arab Muslims and Oriental Jews. Hum Genet 2010; 128:261-267.
5. Liang X, Dong F, Li H, et al. Novel CNGA3 mutations in Chinese patients with achromatopsia. Br J Ophthalmol 2015;99:571-576.
6. Kohl S, Baumann B, Rosenberg T, et al. Mutations in the cone photoreceptor G-protein a-subunit gene GNAT2 in patients with achromatopsia. Am J Hum Genet 2002;71:422-425.
7. Chang B, Grau T, Dangel S, et al. A homologous genetic basis of the murine cpfl1 mutant and human achromatopsia linked tomutations in the PDE6C gene. Proc Natl Acad Sci U S A 2009;106:19581-19586.
8. Thiadens AA, Slingerland NW, Roosing S, et al. Genetic etiology and clinical consequences of complete and incomplete achromatopsia. Ophthalmology 2009;116:1984-1989.
9. Kohl S, Coppieters F, Meire F, et al. A nonsense mutation in PDE6H causes autosomal-recessive incomplete achromatopsia. Am J Hum Genet 2012; 91:527-532.
10. Bainbridge JW, Mehat MS, Sundaram V, et al. Long-term effect of gene therapy on Leber's congenital amaurosis. N Engl J Med 2015;372: 1887-1897.
11. Jacobson SG, Cideciyan AV, Ratnakaram R, et al. Gene therapy for Leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 2012;130:9-24.
12. Jacobson SG, Cideciyan AV, Roman AJ, et al. Improvement and decline in vision with gene therapy in childhood blindness. N Engl J Med 2015;372:1920-1926.
13. Maguire AM, High KA, Auricchio A, et al. Agedependent effects of RPE65 gene therapy for Leber's congenital amaurosis: A phase 1 doseescalation trial. Lancet 2009;374:1597-1605.
14. Michalakis S, Muhlfriedel R, Tanimoto N, et al. Restoration of cone vision in the CNGA3-/-mouse model of congenital complete lack of cone photoreceptor function. Mol Ther 2010;18:2057-2063.
15. Alexander JJ, Umino Y, Everhart D, et al. Restoration of cone vision in a mouse model of achromatopsia. Nat Med 2007;13:685-687.
16. Komáromy AM, Alexander JJ, Rowlan JS, et al. Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet 2010;19:2581-2593.
17. Pang JJ, DengWT, Dai X, et al. AAV-mediated cone rescue in a naturally occurring mouse model of CNGA3-achromatopsia. PLoS One 2012;7:e35250.
18. Carvalho LS, Xu J, Pearson RA, et al. Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy. Hum Mol Genet 2011;20:3161-3175.
19. Michalakis S, Muhlfriedel R, Tanimoto N, et al. Gene therapy restores missing cone-mediated vision in the CNGA3-/-mouse model of achromatopsia. Adv Exp Med Biol 2012;723:183-189.
20. Dyka FM, Boye SL, Ryals RC, et al. Cone specific promoter for use in gene therapy of retinal degenerative diseases. Adv Exp Med Biol 2014; 801:695-701.
21. Klein RL, Hamby ME, Gong Y, et al. Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain. Exp Neurol 2002;176:66-74.
22. Wang Y, Macke JP, Merbs SL, et al. A locus control region adjacent to the human red and green visual pigment genes. Neuron 1992;9:429-440.
23. Zolotukhin S, Byrne BJ, Mason E, et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 1999;6:973-985.
24. Zolotukhin S, Potter M, Zolotukhin I, et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 2002;28:158-167.
25. Kang W, Wang L, Harrell H, et al. An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes. Gene Ther 2009;16:229-239.
26. Timmers AM, Zhang H, Squitieri A, et al. Subretinal injections in rodent eyes: effects on electrophysiology and histology of rat retina. Mol Vis 2001;7:131-137.
27. Komáromy AM, Alexander JJ, Cooper AE, et al. Targeting gene expression to cones with human cone opsin promoters in recombinant AAV. Gene Ther 2008;15:1049-1055.
28. Wu Z, Yang H, and Colosi P. Effect of genome size on AAV vector packaging. Mol Ther 2010; 18:80-86.
29. Yeh CY, Iwabe S, Boye SL, et al. Optimization of cone-directed AAV-mediated gene augmentation therapy for CNGB3-achromatopsia by use of the IRBP/GNAT2-promoter and intravitreal CNTF administration. In: ARVO 2013 Annual Meeting (Seattle, WA), 2013; p. abstract 1937.
30. Ye GJ, Budzynski E, Sonnentag P, et al. Safety and biodistribution evaluation in cynomolgus macaques of rAAV2tYF-CB-hRS1, a recombinant adeno-associated virus vector expressing retinoschisin. Hum Gene Ther Clin Dev 2015;26: 165-176.
31. Li Q, Timmers AM, Guy J, et al. Cone-specific expression using a human red opsin promoter in recombinant AAV. Vision Res 2008;48:332-338.
32. Beltran WA, Cideciyan AV, Guziewicz KE, et al. Canine retina has a primate fovea-like bouquet of cone photoreceptors which is affected by inherited macular degenerations. PLoS One 2014; 9:e90390.